Collegium Pharmaceutical announced the execution of an accelerated share repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. The company paid $50 million upfront and received an initial delivery of 1,556,420 shares based on a closing price of $25.70 on August 12, 2026. This transaction represents approximately 80% of the expected total repurchase under this specific agreement, with final settlement expected by the fourth quarter of 2026. The purchase is part of a broader $150 million share repurchase program authorized in July 2025. As of June 30, 2026, there were approximately 32.5 million shares outstanding. Collegium Pharmaceutical operates in the pharmaceutical industry and develops commercial-stage medicines for pain management.

Collegium Pharmaceutical reported second quarter 2026 financial results, generating quarterly net revenues of $199.9 million, a 6% increase year-over-year. JORNAY PM revenue rose 41% to $46.1 million, while the pain portfolio declined 9% to $140.9 million due to lower Nucynta franchise revenues. The company completed its acquisition of AZSTARYS in May, contributing $12.9 million in partial quarter sales. Collegium updated its full-year 2026 guidance, lowering product revenue net expectations to $825–$855 million and adjusted EBITDA to $445–$470 million, while raising AZSTARYS revenue estimates to $65–$75 million. The company operates in the biopharmaceutical industry, developing and commercializing medicines for central nervous system and pain conditions.

On May 12, 2026, Collegium Pharmaceutical completed the acquisition of AZSTARYS, a CNS stimulant for ADHD, by acquiring GPC Commave Holding, LLC and Commave Sub, LLC from Corium Therapeutics. The aggregate cash consideration was approximately $655.6 million, funded by $355.6 million of existing cash and a $300.0 million delayed draw term loan. The company may pay up to $135 million in additional consideration based on future commercial and manufacturing milestones. This filing provides the required historical financial statements of Corium and pro forma financial information. Collegium Pharmaceutical is a pharmaceutical company that develops and commercializes specialty medicines.